HomeCompareKAJMY vs JNJ

KAJMY vs JNJ: Dividend Comparison 2026

KAJMY yields 2.04% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KAJMY wins by $49.68M in total portfolio value
10 years
KAJMY
KAJMY
● Live price
2.04%
Share price
$37.72
Annual div
$0.77
5Y div CAGR
97.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.71M
Annual income
$45,005,855.70
Full KAJMY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KAJMY vs JNJ

📍 KAJMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKAJMYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KAJMY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KAJMY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KAJMY
Annual income on $10K today (after 15% tax)
$173.52/yr
After 10yr DRIP, annual income (after tax)
$38,254,977.35/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KAJMY beats the other by $38,250,991.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KAJMY + JNJ for your $10,000?

KAJMY: 50%JNJ: 50%
100% JNJ50/50100% KAJMY
Portfolio after 10yr
$24.87M
Annual income
$22,505,272.55/yr
Blended yield
90.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KAJMY
No analyst data
Altman Z
2.5
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KAJMY buys
0
JNJ buys
0
No recent congressional trades found for KAJMY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKAJMYJNJ
Forward yield2.04%2.13%
Annual dividend / share$0.77$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR97.9%28%
Portfolio after 10y$49.71M$30.3K
Annual income after 10y$45,005,855.70$4,689.40
Total dividends collected$49.33M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KAJMY vs JNJ ($10,000, DRIP)

YearKAJMY PortfolioKAJMY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,104$403.98$10,592$272.30+$512.00KAJMY
2$12,711$829.67$11,289$357.73+$1.4KKAJMY
3$15,357$1,756.57$12,123$472.89+$3.2KKAJMY
4$20,358$3,925.23$13,141$629.86+$7.2KKAJMY
5$31,406$9,623.60$14,408$846.81+$17.0KKAJMY
6$61,064$27,459.30$16,021$1,151.60+$45.0KKAJMY
7$164,085$98,746.39$18,122$1,588.22+$146.0KKAJMY
8$666,328$490,757.69$20,930$2,228.20+$645.4KKAJMY
9$4,398,920$3,685,948.43$24,792$3,191.91+$4.37MKAJMY
10$49,712,700$45,005,855.70$30,274$4,689.40+$49.68MKAJMY

KAJMY vs JNJ: Complete Analysis 2026

KAJMYStock

Kajima Corporation engages in civil engineering, building construction, and real estate development and other businesses worldwide. It provides procurement and construction services comprising sale and lease of construction equipment and materials, and subcontracting for various construction projects; ground improvement, foundation construction, and soil remediation; paving of roads, bridges, airports, etc., as well as manufacture and sale of paving materials; ocean port and coastal protection work, and geological surveying; calculation and preparation of construction plans; environmental and consulting work focused on water and waste; construction machinery manufacturing; repair and reinforcement work for civil engineering structures, and sale of repair materials; and integrated facility construction, and renovation services. The company also offers building management services; leasing and operational management services of real estate, and hotel management; and brokerage and appraisal services of real estate. In addition, it provides travel agency, product sales, and business services; temporary staffing and human resources placement, and events planning services; planning of construction projects, and building and equipment leasing; design, operation, and management of information communication technology infrastructure and various computer systems; collection, transportation, and processing of waste; public relations and advertising planning and production, as well as video production services; and real estate asset management and consulting, as well as buying, selling, and brokerage of beneficial interests of a trust. Further, the company offers book publishing; hotel, golf course, and ski resort services; and architectural and civil engineering design, engineering, greening landscaping, mountain forest management, and agency handling services of property, casualty, and life insurance. The company was founded in 1840 and is headquartered in Tokyo, Japan.

Full KAJMY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KAJMY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KAJMY vs SCHDKAJMY vs JEPIKAJMY vs OKAJMY vs KOKAJMY vs MAINKAJMY vs ABBVKAJMY vs MRKKAJMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.